Monoclonal antibody treatment by Eli Lilly found to cut risk of serious COVID-19, drugmaker reports
A study of nursing home residents found the monoclonal antibody treatment bamlanivimab cut risk of COVID-19 by up to 80%, maker Eli Lilly announced.
Related Articles
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nature Medicine – In a phase 2 trial, the oral type II RAF inhibitor tovorafenib exhibited an overall response rate of 67% in patients with…
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
Nature Reviews Clinical Oncology – Recent results from the FLAURA2 and MARIPOSA-2 trials underline the continued role of chemotherapy in the treatment of patients with…
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers
Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or…
AI’s Threat to the Medical Profession
This Viewpoint discusses the potential drawbacks of the use of artificial intelligence (AI) in medicine, for example, the loss of certain skills due to the…
What Clinicians Need to Know About TikTok
This Medical News article discusses research on health information being shared on the social media platform.
A Vision for Democratizing Next-Generation Oncology Clinical Trials
Summary:. Revolutionary advancements in oncology have transformed lives, but the clinical trials ecosystem encounters challenges, including restricted access to innovative therapies and a lack of…
A Vision for Democratizing Next-Generation Oncology Clinical Trials
Summary:. Revolutionary advancements in oncology have transformed lives, but the clinical trials ecosystem encounters challenges, including restricted access to innovative therapies and a lack of…
Baylor wins 2024 STAT Madness with ‘smoke alarm’ for viral disease outbreaks
A Baylor study demonstrating the power of sewage as an early-warning system for viral disease outbreaks won the 2024 STAT Madness popular vote.
Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access
This clinical care review summarizes government policies for the safe conduct of clinical trials using the telehealth and decentralized clinical trials digital health models.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.